Albemarle — Feb 11, 2026 release

Production volume in 2026 is expected to be impacted by a major flooding event that occurred at our Jordan Bromine Company (JBC) joint venture in January 2026. JBC has since returned to full operating rates. 3 Segment FY 2026E Specialties net sales $1.2 - $1.4 billion Specialties adjusted EBITDA $170 - $230 million Other Corporate Outlook Considerations Following the sale of a controlling stake in Ketjen, which is expected to close in the first quarter of 2026, the refining catalyst business earnings will be classified as equity income and included in Corporate, as will the results of the retained Performance Catalyst Solutions (PCS) business. The EBITDA and equity income contributions from these are expected to be immaterial post transaction. Albemarle expects its 2026 capital expenditures to be roughly flat compared to 2025, in the range of $550 million to $600 million. Other Corporate FY 2026E Capital expenditures $550 - $600 million Depreciation and amortization $660 - $680 million Adjusted effective tax rate (a) (50%) - 30% Corporate adjusted EBITDA (incl. FX, Ketjen equity income & PCS) ($20) - $20 million Interest and financing expenses $150 - $170 million Weighted-average common shares outstanding (diluted) ~118 million (a)    Adjusted effective tax rate dependent on lithium market prices and geographic income mix Cash Flow and Capital Deployment Cash from operations of $1.3 billion for the year ended December 31, 2025 increased $594 million compared to the prior-year period due to c